TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis
Annals of Rheumatic Diseases, 05/08/2012
Zonneveld–Huijssoon E et al. – These clinical and immunological data suggest the use of CpG as a potent adjuvant for mucosal peptide–specific immune therapy in arthritis.



